Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult.
In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease.
This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive.
Learning Objectives
- What are strategies to optimise surveillance and early diagnosis of hepatocellular carcinoma
- What are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy)
- Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapy
